CoChat

Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus

Lai, Lee-Lee, Vethakkan, Shireene Ratna, Nik Mustapha, Nik Raihan, Mahadeva, Sanjiv, Chan, Wah-Kheong · 2020 · Digestive Diseases and Sciences

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background and aims Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of drugs that lower glucose by inducing renal glycosuria. We aimed to explore whether SGLT2 inhibitor added to the usual care for patients with type 2 diabetes mellitus (T2DM) and biopsy-proven nonalcoholic steatohepatitis (NASH) will benefit NASH histology. Methods In this investigator-initiated, single-arm, open-label, pilot study, nine biopsy-proven NASH patients with T2DM were given empagliflozin 25 mg daily for 24 weeks. Liver biopsy was repeated at the end of treatment. The histological outcomes were compared with the placebo group of a previous 48-week clinical trial. Results There was a significant reduction in body mass index (median change, Δ = -0.7 kg per m 2 , p = 0.011), waist circumference (Δ = -3 cm, p = 0.033), systolic blood pressure (Δ = -9 mmHg, p = 0.024), diastolic blood pressure (Δ = -6 mmHg, p = 0.033), fasting blood glucose (Δ = -1.7 mmol/L, p = 0.008), total cholesterol (Δ = -0.5 mmol/L, p = 0.011), gamma glutamyl transpeptidase (Δ = -19 U/L, p = 0.013), volumetric liver fat fraction (Δ = -7.8%, p = 0.017), steatosis (Δ = -1, p = 0.014), ballooning (Δ = -1, p = 0.034), and fibrosis (Δ = 0, p = 0.046). All histological components either remained unchanged or improved, except in one patient who had worsening ballooning. Empagliflozin resulted in significantly greater improvements in steatosis (67% vs. 26%, p = 0.025), ballooning (78% vs. 34%, p = 0.024), and fibrosis…

Overview

Integrity signals

Registry

Crossref · 10.1007/s10620-019-5477-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 192

Metadata

Authors
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K.
Affiliations
University of Malaya (MY)
Corresponding author
  • Vethakkan, Shireene Ratna
  • Chan, Wah-Kheong
Venue
Digestive Diseases and Sciences
Published
2019-01-25
Volume
65
Issue
2
Pages
623-631
ISSN
  • 0163-2116 (ISSN-L)
  • 1573-2568
OpenAlex
W2912523003
Cited by
191
References
33
Citations by year
2026: 10 · 2025: 30 · 2024: 25 · 2023: 26 · 2022: 34 · 2021: 24 · 2020: 30 · 2019: 12
FWCI
19.21
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Digestive Diseases and Sciences (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Malaya Special Research Fund (Project No.: BK006-2016, BKS067-2017)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
empagliflozin, nonalcoholic steatohepatitis, type 2 diabetes, SGLT2 inhibitors, liver histopathology, steatosis, liver fibrosis, ballooning, liver fat fraction, gamma-glutamyl transferase, renal glycosuria, pilot study
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Biopsy, Blood Glucose, Blood Pressure, Cholesterol, Diabetes Mellitus, Type 2, Female, gamma-Glutamyltransferase, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Pilot Projects, Body Mass Index, Treatment Outcome, Waist Circumference, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1007/s10620-019-5477-1
The paper
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020). Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-019-5477-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.